These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
144 related items for PubMed ID: 2487550
21. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Andrews R, Charlesworth A, Evans A, Cowley AJ. Eur Heart J; 1997 May; 18(5):852-7. PubMed ID: 9152656 [Abstract] [Full Text] [Related]
22. Evaluation of ibopamine plus prazosin in congestive heart failure. Naidoo DP, Rocke A, Mitha AS. S Afr Med J; 1998 Feb; 88 Suppl 1():C25-31. PubMed ID: 9542492 [Abstract] [Full Text] [Related]
23. The efficacy of ibopamine in long-term treatment of dilated cardiomyopathy. A clinical and instrumental evaluation. Benassi A, Modena MG, Mattioli G. Arzneimittelforschung; 1986 Feb; 36(2A):390-4. PubMed ID: 3518726 [Abstract] [Full Text] [Related]
24. Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results. Sher D, Licciardello L, Ferrari V, Sirtori F, Cesana B. Arzneimittelforschung; 1991 Apr; 41(4):402-9. PubMed ID: 1859514 [Abstract] [Full Text] [Related]
25. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. Brouwer J, van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, Boomsma F, Haaksma J, Lie KI. J Am Coll Cardiol; 1995 Oct; 26(4):983-90. PubMed ID: 7560628 [Abstract] [Full Text] [Related]
26. [Comparative study between ibopamine and captopril in mild and moderate heart failure. A double-blind study]. Arcensio SR, Barretto AC, Szambock F, Mady C, Arteaga E, da Luz PL, Bellotti G, Pileggi F. Arq Bras Cardiol; 1994 Nov; 63(5):409-13. PubMed ID: 7611921 [Abstract] [Full Text] [Related]
27. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Spencer C, Faulds D, Fitton A. Drugs Aging; 1993 Nov; 3(6):556-84. PubMed ID: 7906158 [Abstract] [Full Text] [Related]
34. Ibopamine and survival in severe congestive heart failure: PRIME II. Massel D. Lancet; 1997 Jul 12; 350(9071):147. PubMed ID: 9228992 [No Abstract] [Full Text] [Related]
35. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations. Dei Cas L, Metra M, Nodari S, Visioli O. J Cardiovasc Pharmacol; 1989 Jul 12; 14 Suppl 8():S111-7. PubMed ID: 2483436 [Abstract] [Full Text] [Related]
36. Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart failure NYHA class II/III and sinus rhythm. Huonker M, Sorichter S, Schmidt-Trucksäss A, Irmer M, Staiger J, Keul J. Cardiovasc Drugs Ther; 1999 May 12; 13(3):233-41. PubMed ID: 10439886 [Abstract] [Full Text] [Related]
37. Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects. López-Sendón J. Am J Med; 1991 May 29; 90(5B):43S-49S. PubMed ID: 1675551 [Abstract] [Full Text] [Related]
38. Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure. Gavazzi A, Mussini A, Bramucci E. Arzneimittelforschung; 1986 Feb 29; 36(2A):366-70. PubMed ID: 3707652 [Abstract] [Full Text] [Related]